Clinical trials: Mild to Moderate Hypertension
Hypertension
Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.
- Trial name
- NCT00376636
- Testing
- SPP635 (drug)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Speedel Pharma Ltd.
Hypertension, Ankle Edema
Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension
The purpose of the present study was to evaluate the addition of aliskiren, to amlodipine can attenuate ankle edema formation in hypertensive patients.
- Trial name
- NCT01080768
- Testing
- Aliskiren/amlodipine, Amlodipine
- Where
- 9 sites in Netherlands
- Volunteers
- 31 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With Hypertension
This study evaluated the safety and efficacy of the fixed combination of valsartan/amlodipine in adult patients with mild to moderate hypertension.
- Trial name
- NCT00413413
- Testing
- Valsartan/amlodipine 80/5 mg, Valsartan 80 mg, Valsartan 160 mg
- Where
- 19 sites in China
- Volunteers
- 1,134 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
A Trial Comparing MICARDIS® (Telmisartan) and COZAAR® (Losartan) in Patients With Mild-to-Moderate Hypertension Using Ambulatory Blood Pressure Monitoring (ABPM)
The primary aim of the trial is to compare the influence of MICARDIS® (telmisartan 40-80 mg) and COZAAR® (losartan 50-100 mg) in lowering ambulatory diastolic blood pressure (DBP) during the last 6 hours of the 24-hour dosing…
- Trial name
- NCT02200640
- Testing
- High dose of Micardis®, once daily, Low dose of Micardis®, once daily, Low dose of COZAAR®, once daily
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
Essential Hypertension
A Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan (BR-A-657•K) During 24 Hours in Patients With Mild to Moderate Essential Hypertension
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) during 24 hours by dose in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922441
- Testing
- Fimasartan 60 mg group, Fimasartan 120 mg group, Reference (Valsartan 80 mg) group
- Volunteers
- 92 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd